The potential biomedical benefits of consuming stabilized amorphous calcium carbonate (ACC) as preferred source for calcium supplement were inspired by discovering the mode of generating and utilizing stabilized ACC in nature. This revolutionary concept was initiated after Amorphical’s founder, Yossi Ben, was amazed to discover that a cultivated freshwater crayfish, named Cherax Quadricarinatus, can rapidly …

Nanoparticulate amorphous calcium carbonate (ACC) is the initial and highly unstable phase in the crystallization of crystalline calcium carbonate, one of the most abundant minerals in its rock form (mainly as calcite and aragonite crystals).

Ever since its role in the prevention of osteoporosis in humans was proven some 40 years ago, calcium bioavailability has been the subject of numerous research studies, being the basis of the various calcium supplements’ ability to release calcium ions that shall reach and bind to the bones. Amorphical was the first company to develop …

Amorphical has shown an increase in calcium bioavailability in rats administered with synthetic, stable Amorphous Calcium Carbonate (ACC) in comparison to crystalline calcium carbonate (CCC). This study sought to see whether the superior bioavailability indeed manifests improved bone mass density in an animal osteoporosis model. The study compared the effects of stabilized ACC derived from …

This double-blind randomized crossover clinical trial compared the bioavailability of stabilized ACC to that of CCC. The trial was conducted by Prof. Nachum Vaisman in Sourasky Medical Center in Tel Aviv. To trace the calcium ions administered by means of calcium tablets, two unique calcium isotopes were used (44Ca and 42Ca). The study population consisted …